Cover Image
市場調查報告書

重組注射劑的整合設備

Integrated Devices for Reconstituting Injectables

出版商 Greystone Research Associates 商品編碼 356827
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
重組注射劑的整合設備 Integrated Devices for Reconstituting Injectables
出版日期: 2016年04月25日 內容資訊: 英文
簡介

本報告以整合藥物的重組次序與注射次序的重組注射劑用設備為主題,提供冷凍乾燥注射藥目前帶給治療市場的影響,整合型重組設備的供應商與其對市場的影響,注射藥重組整合型設備的主要需求促進要素,整合型藥物重組系統藥物對生命週期管理的影響,經濟、技術、規定上的要素帶給注射藥、重組系統市場的影響等相關分析。

摘要整理

藥物重組市場動態

  • 設備設計的演進
  • 處方要素
  • 產品專用的設備開發
  • 特殊注射設備的需求促進要素
    • 慢性疾病、自我施打
    • 生技藥品的擴大
    • 處方、服藥
    • 患者統計的變化
    • 藥物的經濟學,安全性及遵守
    • 設備設計、創新

競爭情形

  • 技術市場促進要素

重組注射劑用整合設備

  • 雙心腔型匣
  • 雙心腔型注射器
  • 雙心腔型注射器
  • 穿戴式設備自動重組系統

雙心腔型注射器 & 注射器設備的評估

  • 產品專用設備
  • 特殊設備
  • OEM設備

治療區分:市場資料 & 預測

  • 血糖管理
  • 遺傳性疾病
  • 荷爾蒙補充
  • 感染疾病
  • 代謝狀態
  • 癌症
  • 生殖健康
  • 其他治療區分

市場要素

  • 設備的產品策略
  • 設備的經濟學
  • 產品的品牌
  • 直銷行銷
  • 管理護理趨勢

企業簡介

目錄
Product Code: JDR299F

The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed. Alternatively, proteins can be formulated as powders (lyophilization) and must be reconstituted prior to injection. Historically, this was accomplished by including a disposable syringe and diluent vial for manual reconstitution. As the number of drugs developed for self-administration has grown, devices that integrate a reconstitution step with the injection step have gained traction. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.

What You Will Learn

  • What is the impact of lyophilized injectable drugs on today's therapeutic market, how are they packaged, and who markets them?
  • Who are the suppliers of integrated reconstitution devices, and what is their market impact?
  • What are the major factors driving the demand for integrated devices for injectable drug reconstitution?
  • What is the relative impact of integrated reconstitution systems to OEM or standalone reconstitution devices and how will this change by the end of the decade?
  • What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?
  • What is the role of integrated drug reconstitution systems on drug life cycle management?
  • What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems in particular?

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

‘Currently only a small number of lyophilized drugs are supplied in integrated reconstitution devices - most lyophilized drugs for injection are typically sold in vials packaged with a diluent syringe - but this number is expanding with the growing number of branded injectables that cannot be stored as liquids at room temperature. The simplicity and patient acceptance of integrated reconstitution devices is becoming an accepted method for differentiating injectables in an increasingly competitive market.’

Table of Contents

  • Executive Summary
  • Drug Reconstitution Market Dynamics
  • Evolution in Device Design
  • Formulation Factors
  • Product Specific Device Development
  • Specialty Injection Device Demand Drivers
    • Chronic Conditions and Self-Administration
    • The Growth of Biologicals
    • Formulation and Dosing
    • Shifting Patient Demographics
    • Drug Economics, Safety and Compliance
    • Device Design and Innovation
  • Competitive Landscape
  • Technology Market Drivers
  • Integrated Devices for Reconstituting Injectables
  • Dual Chamber Cartridges
  • Dual Chamber Injectors
  • Dual Chamber Syringes
  • Wearable Device Automated Reconstitution System
  • Dual Chamber Syringe & Injector Device Assessments
  • Product-Specific Devices
  • Specialty Devices
  • OEM Devices
  • Therapeutic Segments - Market Data & Forecasts
  • Glycemic Control
  • Hereditary Conditions
  • Hormone Replacement
  • Infectious Disease
  • Metabolic Conditions
  • Oncology
  • Reproductive Health
  • Other Therapeutic Segments
  • Market Factors
  • Device Product Strategies
  • Device Economics
  • Product Branding
  • Direct-to-Consumer Marketing
  • Managed Care Trends
  • Company Profiles
Back to Top